Your browser doesn't support javascript.
loading
Osilodrostat - an emerging drug for the medical management of Cushing's disease.
Witek, Przemyslaw; Mehlich, Anna; Stasiewicz, Aleksandra; Jawiarczyk-Przybylowska, Aleksandra; Bolanowski, Marek.
Afiliación
  • Witek P; Department of Internal Medicine, Endocrinology, and Diabetes, Medical University of Warsaw, Poland. pwitek@wum.edu.pl.
  • Mehlich A; Department of Internal Medicine, Endocrinology, and Diabetes, Medical University of Warsaw, Poland.
  • Stasiewicz A; Department of Internal Medicine, Endocrinology, and Diabetes, Medical University of Warsaw, Poland.
  • Jawiarczyk-Przybylowska A; Chair and Department of Endocrinology, Diabetes, and Isotope Treatment, Wroclaw Medical University, Wroclaw, Poland.
  • Bolanowski M; Chair and Department of Endocrinology, Diabetes, and Isotope Treatment, Wroclaw Medical University, Wroclaw, Poland.
Endokrynol Pol ; 73(2): 371-374, 2022.
Article en En | MEDLINE | ID: mdl-35381096
Cushing's disease (CD) is a rare endocrine disorder characterized by the overproduction of adrenocorticotropic hormone (ACTH) by pituitary adenoma followed by hypercortisolaemia with severe complications. Although transsphenoidal resection of the defined pituitary adenoma has been the treatment of choice for the past decades, it does not always result in long-term remission - 10-30% of cases show ineffective surgical treatment or tumour recurrence even after initial success. Pharmacological therapies for cortisol reduction are often required for those who either cannot undergo pituitary surgery or when the surgery has failed, and patients still present with the persistent disease. Osilodrostat is a potent oral steroidogenesis inhibitor that has lately been shown as an effective adjuvant therapy in the management of patients with CD. In this article, we review the recent reports on the efficacy and safety of osilodrostat in clinical settings.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Piridinas / Hipersecreción de la Hormona Adrenocorticotrópica Pituitaria (HACT) / Imidazoles Límite: Humans Idioma: En Revista: Endokrynol Pol Año: 2022 Tipo del documento: Article País de afiliación: Polonia Pais de publicación: Polonia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Piridinas / Hipersecreción de la Hormona Adrenocorticotrópica Pituitaria (HACT) / Imidazoles Límite: Humans Idioma: En Revista: Endokrynol Pol Año: 2022 Tipo del documento: Article País de afiliación: Polonia Pais de publicación: Polonia